Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Singapore's Ion Investments Buys Another 10% Stake In Korea's Celltrion In Anticipation of 2012 Biosimilars Launch

This article was originally published in PharmAsia News

Executive Summary

SEOUL - Celltrion, Inc. said Sept. 1 that Singapore's Ion Investments B.V., a wholly-owned subsidiary of Temasek Holdings Pte. Ltd., purchased 10% of the outstanding shares of Celltrion Healthcare Co., Celltrion's global distribution and marketing arm, increasing the investor's share in the Korean company

You may also be interested in...



Celltrion Nearly Triples Production Capability For Biosimilars In Anticipation Of Global Launches

SEOUL - South Korea's biosimilar front-runner Celltrion, Inc. will begin production at a new 90,000-liter manufacturing plant Oct. 5 located at its main plant in Incheon City

Celltrion Nearly Triples Production Capability For Biosimilars In Anticipation Of Global Launches

SEOUL - South Korea's biosimilar front-runner Celltrion, Inc. will begin production at a new 90,000-liter manufacturing plant Oct. 5 located at its main plant in Incheon City

Korea's Celltrion Sees Growth Trend Continue On Strength Of Biosimilar Validation Batch Orders

SEOUL - Celltrion, Inc. retained upward momentum in its earnings for the second quarter thanks to continued strong shipment of validation batches for biosimilars of Roche's breast cancer agent Herceptin (trastuzumab) and Johnson & Johnson's rheumatoid arthritis drug Remicade (infliximab)

Related Content

UsernamePublicRestriction

Register

LL1134409

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel